[
  {
    "ts": "2025-11-26T01:52:57+00:00",
    "headline": "Trump administration slashes Ozempic and Wegovy price for Medicare",
    "summary": "The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...",
    "url": "https://finance.yahoo.com/news/trump-administration-slashes-ozempic-wegovy-015257263.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "40d79c9f-00e1-3ebf-a1af-7058a1562a2c",
      "content": {
        "id": "40d79c9f-00e1-3ebf-a1af-7058a1562a2c",
        "contentType": "STORY",
        "title": "Trump administration slashes Ozempic and Wegovy price for Medicare",
        "description": "",
        "summary": "The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...",
        "pubDate": "2025-11-26T01:52:57Z",
        "displayTime": "2025-11-26T01:52:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/ecd6aca0-ca7d-11f0-bbdf-308e30c26b49",
          "originalWidth": 5800,
          "originalHeight": 3856,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5GN.xl0yoOZ9rASn727bRg--~B/aD0zODU2O3c9NTgwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/ecd6aca0-ca7d-11f0-bbdf-308e30c26b49.cf.webp",
              "width": 5800,
              "height": 3856,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Ur0b.rYqO.iixKcxBvlnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/ecd6aca0-ca7d-11f0-bbdf-308e30c26b49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trump-administration-slashes-ozempic-wegovy-015257263.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trump-administration-slashes-ozempic-wegovy-015257263.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-26T06:08:31+00:00",
    "headline": "JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]",
    "url": "https://finance.yahoo.com/news/jpmorgan-raises-eli-lilly-lly-060831576.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "61674905-f2f8-3d11-934b-57c04205981e",
      "content": {
        "id": "61674905-f2f8-3d11-934b-57c04205981e",
        "contentType": "STORY",
        "title": "JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]",
        "pubDate": "2025-11-26T06:08:31Z",
        "displayTime": "2025-11-26T06:08:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/30173640c9b0cffb6b7013930030fa3e",
          "originalWidth": 1920,
          "originalHeight": 1275,
          "caption": "JPMorgan Raises Eli Lilly (LLY) Price Target to $1,150, Maintains Overweight Rating",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TkRKqkPAOo0eEJXaJY9Y2A--~B/aD0xMjc1O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/30173640c9b0cffb6b7013930030fa3e.cf.webp",
              "width": 1920,
              "height": 1275,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pTG9ApYeTSmSfYp_rFmJ.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/30173640c9b0cffb6b7013930030fa3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jpmorgan-raises-eli-lilly-lly-060831576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpmorgan-raises-eli-lilly-lly-060831576.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-26T09:15:00+00:00",
    "headline": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
    "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
    "url": "https://www.fool.com/investing/2025/11/26/did-pfizer-just-say-checkmate-to-novo-nordisk/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a9c76fd0-7f7e-3291-8da7-35ab07377880",
      "content": {
        "id": "a9c76fd0-7f7e-3291-8da7-35ab07377880",
        "contentType": "STORY",
        "title": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
        "description": "",
        "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
        "pubDate": "2025-11-26T09:15:00Z",
        "displayTime": "2025-11-26T09:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4fcfd60229c3102295f150f35c7f44a9",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor works on a laptop at home.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d5go1zahkMsoTLoejEiWtQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4fcfd60229c3102295f150f35c7f44a9.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uPTcf6UgoVqg6lmpUaUE7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4fcfd60229c3102295f150f35c7f44a9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/26/did-pfizer-just-say-checkmate-to-novo-nordisk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-pfizer-just-checkmate-novo-091500358.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]